Break it Down: Recce Pharmaceuticals gets Indonesian entry for clinical trial
Stockhead TV’s Sarah Hughan brings you today’s Break it Down, detailing the new diabetic foot infection treatment trial from Recce Pharmaceuticals.
Stockhead's Break it Down brings you today's leading market news in under 90 seconds.
In this episode, host Sarah Hughan tells all on Recce Pharmaceuticals' (ASX:RCE) approval from the Indonesian Government for a phase 3 clinical trial of its topical gel for diabetic foot infections.
The risk of a person with diabetes developing a foot ulcer has been estimated to be as high as 34% and about half of all diabetic foot ulcers develop infection which can even lead to death.
Tune in to get the latest.
While Recce Pharmaceuticals is a Stockhead advertiser, it did not sponsor this content.
Originally published as Break it Down: Recce Pharmaceuticals gets Indonesian entry for clinical trial
Record prices reignite the race for the next Hemi
Junior explorers are beefing up drilling efforts in the Pilbara as record gold prices reignite search for the next Hemi.
ASX health stocks tackling rare diseases
Rare diseases have become an attractive target for pharmaceutical companies both on the ASX and internationally.
Cashed up GWR chasing ‘game changer’
Cash, they say, is king, and GWR ended last year with $37.5 million in its pocket. Now it wants to add a company making project to its portfolio.